Biocryst Pharmaceuticals Inc. BCRX

NAS: BCRX | ISIN: US09058V1035 14/04/2026

9,670 USD (+2,76%)

(+2,76%) 14/04/2026

Grafiek Biocryst Pharmaceuticals Inc.

Grafiek Biocryst Pharmaceuticals Inc.

1 dag1d 2,76%
1 week1w 0,83%
1 maand1m 3,98%
3 maanden3m 42,63%
6 maanden6m 50,62%
1 jaar1j 37,36%
5 jaar5j -5,10%

Biocryst Pharmaceuticals Inc. in het nieuws

Toon enkel gratis nieuws

27 juni 2025 · BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million · Persbericht

19 maart 2021 · BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development Officer · Persbericht

11 maart 2021 · Early Access to BioCryst’s Berotralstat Granted for HAE Patients in France · Persbericht

25 februari 2021 · BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema · Persbericht

9 februari 2021 · BioCryst to Present Data at 2021 American Academy of Allergy, Asthma & Immunology Annual Meeting · Persbericht

3 februari 2021 · BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older · Persbericht

22 januari 2021 · BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema · Persbericht

7 januari 2021 · BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

6 januari 2021 · BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference · Persbericht

Profiel Biocryst Pharmaceuticals Inc.

Gezondheidstechnologie

Productie van biologische producten

Website: www.biocryst.com

Hoofdzetel: Durham, North Carolina Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe